Research Papers:

c-Met, CREB1 and EGFR are involved in miR-493-5p inhibition of EMT via AKT/GSK-3β/Snail signaling in prostate cancer

Song Wang, Xiao Wang, Jiangfeng Li, Shuai Meng, Zhen Liang, Xin Xu, Yi Zhu, Shiqi Li, Jian Wu, Mingjie Xu, Alin Ji, Yiwei Lin, Ben Liu, Xiangyi Zheng, Bo Xie _ and Liping Xie

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:82303-82313. https://doi.org/10.18632/oncotarget.19398

Metrics: PDF 1756 views  |   HTML 2385 views  |   ?  


Song Wang1,*, Xiao Wang1,*, Jiangfeng Li1, Shuai Meng2, Zhen Liang1, Xin Xu1, Yi Zhu1, Shiqi Li1, Jian Wu1, Mingjie Xu1, Alin Ji2, Yiwei Lin1, Ben Liu1, Xiangyi Zheng1, Bo Xie3 and Liping Xie1

1Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People’s Republic of China

2Department of Urology, Zhejiang Provincial People’s Hospital, Hangzhou, Zhejiang Province, People’s Republic of China

3Department of Urology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang Province, People’s Republic of China

*These authors have contribute equally to this work

Correspondence to:

Bo Xie, email: [email protected]

Liping Xie, email: [email protected]

Keywords: prostate cancer, miR-493-5p, c-Met, CREB1, EGFR

Received: April 21, 2017    Accepted: June 24, 2017    Published: July 19, 2017


miR-493-5p downregulation has emerged as a critical player in cancer progression yet, the underlying mechanisms of miR-493-5p expression pattern and its function in prostate cancer remains to be elucidated. Here, we illustrate that miR-493-5p is frequently downregulated in prostate cancer, at least partially due to altered DNA methylation. miR-493-5p functions as a tumor suppressor in prostate cancer cells. c-Met, CREB1 and EGFR are downstream target genes of miR-493-5p. miR-493-5p inhibits EMT via AKT/GSK-3β/Snail signaling in prostate cancer. Taken together, our study identified c-Met, CREB1, EGFR and miR-493-5p establish a regulatory loop in prostate cancer, which could prove useful in the development of effective and therapies against prostate cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19398